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The effect of omega-3 fatty acid supplementation on
plasma orexin A, plasma fatty acids, and anthropometric
measurements in patients with narcolepsy
Makbule GEZMEN KARADAĞ1, Meral AKSOY2

Aim: To determine the effect of omega-3 (n-3) fatty acid supplementation on plasma orexin A, plasma fatty acids, and
anthropometric measurements in patients with narcolepsy.
Materials and methods: The study was performed on 17 males with narcolepsy and 14 healthy males between the ages
of 21-55. An n-3 fatty acid supplement of 1.4 g/day was administered to the groups for 2 months. The anthropometric
measurements of the individuals were taken at the onset and the end of trial, and orexin, fatty acids, and other
biochemical parameters in the plasma were analyzed.
Results: While there was no statistically significant change in anthropometric measurements or the other body
composition values of the patient group (P > 0.05), there was a statistically significant increase in the body weight, body
mass index, waist-to-hip ratio, and body fat mass values (kg, %) of the control group (P < 0.05). There was no difference
in the levels of plasma orexin A of the patients within or between groups in the pre- and poststudy measurements (P
> 0.05). The poststudy plasma serotonin levels of the patients were lower and plasma insulin levels were higher than in
the initial study (P < 0.05). There was a correlation between the plasma orexin A levels and plasma n-3 fatty acids in
individuals in the control group at the onset of the study (P < 0.05). Depending on the increase of the fatty acids after
the n-3 supplementation, a correlation between plasma orexin A levels and some fatty acids was observed (P < 0.05).
Conclusion: The data demonstrated that supplementation of n-3 fatty acid did not enhance the plasma orexin A level
but did affect some other biochemical parameters.
Key words: Narcolepsy, sleep, orexin, n-3 fatty acid, body mass index, anthropometric measurements

Narkolepsili hastalarda omega-3 yağ asit desteğinin plazma oreksin A, plazma yağ
asitleri ve antropometrik ölçümlere etkisi
Amaç: Bu çalışmada narkolepsili hastalarda omega-3 (n-3) yağ asit desteğinin plazma oreksin A, plazma yağ asitleri ve
antropometrik ölçümlere etkisini saptamak amaçlanmıştır.
Yöntem ve gereç: Çalışma, 21-55 yaş arası 31 erkek birey (17 narkolepsili ve 14 sağlıklı) üzerinde yapılmıştır. Gruplara iki
ay süresince günlük 1,4 g n-3 yağ asidi desteği verilmiştir. Çalışma başlangıcında ve sonunda bireylerin antropometrik
ölçümleri alınmış plazmada oreksin, yağ asitleri ve diğer biyokimyasal parametreler analiz edilmiştir.
Bulgular: Çalışma sonunda, hasta grubun antropometrik ölçüm ve diğer vücut bileşim değerlerinde istatistiksel olarak
önemli değişiklik yokken (P > 0,05), kontrol grubunun vücut ağırlığı, beden kitle indeksi, bel/kalça oranı, vücut yağ (kg,
%) değerlerindeki artış istatistiksel açıdan önemli bulunmuştur (P < 0,05). Hastaların çalışma başı ve sonunda plazma
oreksin A düzeylerinde hem grup içi hem de gruplar arasında fark gözlenmemiştir (P > 0,05). Yine hastaların plazma
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seratonin düzeyleri çalışma başına göre, sonunda azalmış, insülin düzeyleri ise yükselmiştir (P < 0,05). Bireylerin grup
içinde plazma n-6/n-3 oranında çalışma sonunda azalma olmasına karşın istatistiksel açıdan önemli değildir (P >
0,05). Plazma n-6/n-3 oranında gruplar arasında ise istatistiksel farklılık görülmüştür (P < 0,05). Kontrol grubundaki
bireylerin çalışma başında plazma oreksin A düzeyi ile plazma n-3 yağ asitleri arasında korelasyon görülmüştür (P <
0,05). Yine çalışmada n-3 suplemantasyonu ardından yağ asitlerinin artmasına bağlı olarak plazma oreksin A düzeyi ile
bazı yağ asitleri arasında korelasyon gözlenmiştir (P < 0,05).
Sonuç: Bu veriler; n-3 yağ asidi desteğinin plazma oreksin A düzeyini yükseltmediğini ancak diğer bazı biyokimyasal
parametreleri etkilediğini göstermektedir.
Anahtar sözcükler: Narkolepsi, uyku, oreksin, n-3 yağ asitleri, beden kütle indeksi, antropometrik ölçümler

Introduction
Narcolepsy, known as a chronic sleep disorder, was
defined by Westphal in 1877 and Gelineau in 1880.
According to the USA Sleep Disorders Association,
the diagnosis in the patient is established by excessive
daytime sleepiness, cataplexy characterized by a
sudden and bilateral loss of muscle tone with preserved
consciousness, sleep paralyses, hallucinations,
polysomnographic tests, and HLA DQB1*0602
genetic scanning. Due to the lower levels of orexin in
patients with narcolepsy, diagnosis in these patients
is also now established by examining their orexin
levels (1,2). The yearly incidence of narcolepsy seen
with cataplexy is 0.74 in 100,000, and the yearly
incidence of narcolepsy without cataplexy is 1.37 in
100,000 (3). The pathophysiology of the disease is not
completely known yet, but in the trials performed, it
has been stated that it may derive from the imbalance
existing between cholinergic and monoaminergic
neurotransmitter systems (4,5). Although there is
no direct treatment for the patients, it is possible
to decrease the frequency of the symptoms (6,7).
Drug administration (amphetamine-like stimulants,
modafinil, tricyclic antidepressants, etc.) and
psychiatric practices are often used in the treatment
of narcolepsy (8).
Recently, orexin, a hypothalamic neuropeptide,
was discovered; its possible roles in the pathology of
narcolepsy have been indicated by various trials and it
has been detected to play a role in sleep/wakefulness
(9,10). It was stated that orexin neurons are very low
in 85%-95% of patients with narcolepsy compared to
nonnarcoleptic individuals (10,11).
Some hypothalamic neuropeptides, such as orexin,
are generally affected by nutritional status and dietary
78

food consumption (12-14). The amount of dietary fat
intake and the types of fatty acids consumed could
also change the neuropeptide expression (15,16). In
a study by Wortley et al. (17), it was demonstrated
that intralipid injections into the perifornical
hypothalamus enhanced the levels of triglycerides
and increased the orexin gene expression in rats. In
a similar study, it was found that there was a positive
relationship between the orexin and triglyceride
levels in the perifornical hypothalamus (13).
It has been stated that fatty acids have an
increasing potential in orexin synthesis. It has also
been determined that there is a positive relation
between orexin neurons and lipid circulation (13,17).
Taking into consideration the role of orexin in
sleep and the effects of dietary fatty acid intake on its
synthesis, this trial was planned by considering that
the supplementation of essential fatty acids would
increase the orexin levels in patients with narcolepsy
and would be able to help the clinical complications
of patients with narcolepsy.
Materials and methods
This trial began with 19 males with narcolepsy and
16 healthy males. In accordance with the protocol, 17
narcoleptic patients and 14 healthy males completed
the trial. According to the study protocol, those with
an allergy to or side effects from omega-3 (n-3) fatty
acids and those using hormone therapy would be
excluded. Since regular medicine usage, including
supplementary vitamin and mineral pills, and
hormone replacement therapy may alter hormone
levels, patients on a regular medicine regime were
also excluded from the study. Healthy subjects were
examined via polysomnographic sleep tests to assess
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whether they had undiagnosed narcolepsy. For these
tests, they had to stay at the hospital for 2 nights
and for 4 daytime sessions of 20 min each. For this
reason, some healthy subjects refused to participate
in the study, and this is why the number of control
subjects was less than the number of case subjects.

The levels of plasma fatty acids (C14:0, C15:0,
C14:1, C16:0, C16:1, C17:0, C17:1, C18:0, C18:1,
C18:2, C18:3, C20:0, C20:1, C20:4, C20:5, C22:0,
C22:1, C22:6, C24:0, and C24:1) were analyzed using
a gas chromatography-mass spectrometer (GC-MS)
(20).

An n-3 fatty acid supplement of 1.4 g was
administered daily to the patients and the healthy
subjects for 2 months. Anthropometric measurements
of the individuals were taken before and after the
study. Plasma orexin, fatty acids, and some other
biochemical measurements were also analyzed.

The level of plasma serotonin was measured by
analysis with ClinRep® HPLC serotonin kits for the
serums obtained from the centrifuged blood taken
(21). Plasma orexin A levels were analyzed using
orexin peptide radioimmunoassay (RIA) kits from
Phoenix Pharmaceuticals (California, USA) with a
RIA device; the levels were studied 2 times (22).

For this study, the ethics committee report was
received from Gülhane Military Medical Academy
(10 June 2008, Number 1491–550–08/1539).
Body weights (kg) and heights (cm) of the
individuals were measured and body mass
index (BMI; kg/m2) was estimated. The weight
measurements were taken in the fasting state in the
mornings while subjects were wearing light clothes.
Height was measured using an inflexible steel meter,
2 m in length, while subjects stood with heels, back,
and shoulders against a wall, with feet together
and head on the Frankfort plane. Waist and hip
circumferences were measured 3 times by means of
the inflexible meter for reliability of results, and the
waist-to-hip ratio was calculated from these values.
Basal metabolic rate (BMR), fat mass (kg, %) and free
fat mass (FFM; kg) were detected with a Tanita TBF300M body composition analyzer (Tanita, Illinois,
USA).
Blood was taken from the individuals after 12 h of
starvation. Plasma glucose, cholesterol, triglyceride,
high-density lipoprotein cholesterol (HDL-C), lowdensity lipoprotein cholesterol (LDL-C), very-lowdensity lipoprotein cholesterol (VLDL-C), insulin,
orexin A, serotonin, and some fatty acids levels were
analyzed.
The levels of glucose, cholesterol, triglyceride,
HDL-C, LDL-C, and VLDL-C in plasma were
measured photometrically with an Olympus AU
2700 biochemistry autoanalyzer using the original
Olympus kits (Olympus, Tokyo, Japan), and the
levels of plasma insulin were measured with a Roche
E-170 device using the original Roche kits (Roche,
Mannheim, Germany) (18,19).

The mean, standard deviation, median, and
minimum and maximum values of data obtained from
the individuals in pre- and poststudy measurements
were estimated. The intragroup difference between
the pre- and poststudy anthropometric and
biochemical parameter values of the individuals and
the intergroup differences were evaluated according
to the Wilcoxon 2-sample test and the MannWhitney U test, respectively. The correlation between
the values of pre- and poststudy measurements was
examined with Spearman’s correlation coefficient.
For all analyses, P < 0.05 was considered statistically
significant.
Results
The study was begun with 19 narcoleptic (32.2 ±
7.50 years old) and 16 healthy males (29.7 ± 10.22
years old), but completed with 17 narcoleptic and 14
healthy males. Table 1 shows the arithmetic averages
of the ages and anthropometric measurements of
the individuals ( X ), standard deviations (SD), and
median and minimum and maximum values.
As seen in Table 1, at the end of the study, while
there was no statistical significance in anthropometric
measurements or other body composition values of
the patient group (P > 0.05), there was a statistically
significant increase in the body weight, BMI, waistto-hip ratio, and body fat mass (kg, %) values of the
control group (P < 0.05). When the anthropometric
measurements and body compositions of the
participants were examined, it was determined
that there was a difference in heights between the
groups, although there was no intragroup difference
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80

1744 ± 229.84

1768 ± 245.04

1

2

59.7 ± 8.92

60.3 ± 8.52

1

2

15.7 ± 6.25

16.8 ± 7.64

1

2

20.3 ± 5.73

20.9 ± 6.32

1

2

0.87 ± 0.06

0.87 ± 0.07

1

2

103.1 ± 7.67

103.6 ± 8.86

1

2

90.1 ± 10.61

90.8 ± 11.20

1

2

25.4 ± 3.55

26.0 ± 4.41

75.4 ± 13.74

77.1 ± 15.04

2

1

2

1

171.8 ± 6.13

32.2 ± 7.50

1683

1713

58.8

59.4

14.5

17.6

19.2

20.4

0.86

0.88

101.0

101.0

88.0

92.0

25.5

26.1

71.7

73.4

172.0

30

Median

* = P < 0.05; P = intragroup P-value; P’= intergroup P-value

BMR (kcal)

Free fat mass (kg)

Fat mass (kg)

Fat mass (%)

Waist-to-hip ratio

HC (cm)

WC (cm)

BMI (kg/m2)

Weight (kg)

Height (cm)

Age (years)

X ± SD

1368-2138

1356-2232

39.5-77.4

40.1-75.6

5.8-29

4.8-35.5

10.5-31.6

9-33

0.77-0.99

0.75-0.98

92.5-117

92-121

74.1-109

69.8-108.5

18.6-32.1

17.9-37.20

54.9-99.3

52.9-107

159-183

23-55

Min-Max

Narcoleptic

–0.80

–0.80

–0.14

–0.42

–0.59

–0.71

–1.21

1.01

–8.77

-

-

Z

0.42

0.42

0.88

0.67

0.55

0.47

0.22

0.31

0.38

-

-

P

1776 ± 163.81

1790 ± 167.55

61.1 ± 5.78

62.0 ± 6.02

13.9 ± 6.79

13.4 ± 6.21

17.7 ± 6.51

17.1 ± 5.94

0.84 ± 0.06

0.83 ± 0.06

100.8 ± 6.60

101.7 ± 5.99

85.4 ± 11.32

85.4 ± 10.15

24.2 ± 3.39

24.1 ± 3.20

75.1 ± 11.17

75.5 ± 10.98

176.6 ± 6.13

29.7 ± 10.22

X ± SD

1799

1814

60.6

62.7

14.8

14.9

18.1

18.0

0.82

0.82

101.0

100.7

84.6

87.0

25.2

25.0

73.4

75.0

176.0

25

Median

1531-2127

1512-2099

52.9-74.3

51.7-74

5.9-26.9

5.4-26.3

9.6-29.1

8.4-28.5

0.73-1.0

0.75-0.97

92-109.5

94-110.5

74-109.5

74-107

19.3-29.8

19.3-29.7

60.5-92.4

60-92.1

164-189

21-51

Min-Max

Control

Table 1. The anthropometric measurements and body composition values of participants, pre- and poststudy.

–2.45

–0.07

–3.30

–3.29

–2.10

–0.77

–1.05

–2.56

–2.54

-

-

Z

0.01*

0.93

0.001*

0.001*

0.03*

0.44

0.29

0.01*

0.01*

-

-

P

0.52

0.55

0.47
0.62

0.28
0.40

0.12
0.22

0.09
0.20

0.56
0.41

0.11
0.20

0.19
0.35

0.76
0.95

0.01*

-

P’
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(P < 0.05). At the end of study, while there was no
statistically significant difference in BMR levels in
the patient group (P > 0.05), there was a statistically
significant increase in BMR levels of the control
group (P < 0.05).
In pre- and poststudy measurements, some
biochemical parameter values of the participants
were examined and are shown in Table 2. It was
determined that there was an increase in the
plasma insulin levels and a decrease in the plasma
serotonin levels of the patient group (P < 0.05).
While the statistical significance of the levels of
plasma triglyceride, HDL-C, and VLDL-C between
the groups at the onset of the study was identified,
a significant difference in the levels of only plasma
triglyceride, VLDL-C, and serotonin was observed at
the end of the study (P < 0.05).
It was detected that the pre- and poststudy median
values of plasma orexin levels of the patient group
were lower than those of the control group. However,
the difference was not significant (P > 0.05). Table 3
shows the plasma fatty acid levels of the participants
pre- and poststudy. As seen in Table 3, a significant
difference in the plasma C17:1, C20:1, C22:1, C24:1,
and C22:6 levels of the patient group was detected
(P < 0.05) at the end of the study. This statistical
difference was not observed in the control group (P >
0.05). There was a statistically significant intergroup
difference in the plasma C16:1, C17:1, C20:4, and
C22:6 levels at the onset of the trial and in the plasma
C22:1, C24:1, and C22:6 levels at the end of the trial
(P < 0.05).
As seen in Table 4, the correlation between plasma
orexin levels and n-3 fatty acids for C20:5 and C22:6
in the control group was detected at the onset of the
trial (P < 0.05). A correlation between plasma orexin
level in the patient group and plasma C16:1, C20:1,
and C22:0 levels was observed at the end of the study
(P < 0.05).
Discussion
Narcolepsy is a chronic sleep disorder. The
disease prevalence in the European Union and
the USA are 0.02% and 0.07%, respectively (3,5).
There is no information about the prevalence of the
disease in Turkey. Because of this, patients ignore

the disease, do not know where the essential centers
for diagnosis are, and do not have the opportunity
to visit these centers. This study was begun with 19
narcoleptic (32.2 ± 7.50 years old) and 16 healthy
males (29.7 ± 10.22 years old), but fully completed
with only 17 narcoleptic and 14 healthy males (Table
1). Limitations of the study may include a relatively
small sample size. Our strict inclusion/exclusion
criteria for recruiting homogeneous subjects may be
in part responsible for this.
The relationship between ideal body weight
and rapid eye movement (REM) and nonrapid eye
movement (NREM) in narcoleptics was demonstrated
in this study. Depending on the disorders in REMNREM sleep, it has been reported that patients may
become obese (23).
In the clinical studies performed, it was detected
that a high BMI level in patients with narcolepsy was
more common than in the healthy subjects. A study
by Chabas et al. (24) determined that the BMI values
of 13 narcoleptics were higher (25.8 kg/m2) than
those of 9 healthy individuals (22.9 kg/m2). In this
study, a statistically significant difference between the
groups was not found. The BMI values of the patients
with narcolepsy (prestudy: 26 kg/m2, poststudy:
25.4 kg/m2) were within normal ranges, as were the
BMI values of the participants in the control group
(prestudy: 24.1 kg/m2, poststudy: 24.2 kg/m2) (P >
0.05).
As mentioned above, the tendency toward obesity
as well as the high BMI values in patients with
narcolepsy could be explained by a low BMR level.
In a study by Chabas et al. (24), it was observed that
BMR was lower in 13 narcoleptic patients than in 9
healthy individuals (P > 0.05). It was determined that
BMR values of the patients in this study were within
the normal ranges and a difference in BMR levels was
not observed in the patients at the end of the study
(P > 0.05).
Williams et al. (25) administered daily n-3 fatty
acid supplements of 2.7 g to 14 healthy individuals
for 6 weeks without applying a special diet and
determined that there was no difference in the body
weights (P > 0.05). However, as seen in Table 1, there
was an increase in the levels of body fat mass and
body weights of the control group after n-3 fatty acid
supplementation in this study (P < 0.05). In spite of
81

82

10.9 ± 7.20

6.7 ± 1.17

2.6 ± 0.92

1

2

6.8 ± 3.70

1

2

10.6 ± 9.22

14.5 ± 12.2

1

2

30.4 ± 6.05

31.5 ± 4.78

1

2

110.0 ± 36.03

110.0 ± 36.71

1

2

31.4 ± 19.65

33.2 ± 20.81

1

2

44.5 ± 8.71

2

45.3 ± 10.19

149.0 ± 74.45

1

1

185.0 ± 52.93

2

151.0 ± 82.30

187.4 ± 44.67

1

2

88.0 ± 10.71

85.7 ± 9.66

2

1

2.5

7.1

8.8

6.8

6.5

9.6

30.1

30.1

106.0

115.0

26.0

28.0

44.0

45.0

132.0

138.0

170.0

180.0

90.0

85.0

Median

* = P < 0.05; P = intragroup P-value; P’ = intergroup P-value

Plasma
Ratio of n-6 to n-3

Insulin (μU/mL)

Serotonin (nmol/L)

Orexin (pg/mL)

LDL-C (mg/dL)

VLDL-C (mg/dL)

HDL-C (mg/dL)

Triglyceride (mg/dL)

Total cholesterol
(mg/dL)

Glucose (mg/dL)

X ± SD

1.1-4.2

4.7-7.6

3.4-32

1.9-12.7

2.4-32.7

4-43

14-39.7

23.2-40.3

42-173

43-171

11-87

14-91

31-61

28-78

57-336

46-346

105-271

105-276

64-111

66-109

Min-Max

Narcoleptic

–1.604

–2.53

–2.58

–0.26

–0.61

–0.71

–0.02

–0.87

–0.41

–1.63

Z

0.10

0.01*

0.01*

0.79

0.53

0.47

0.97

0.38

0.67

0.10

P

1.9 ± 0.68

4.0 ± 2.96

9.0 ± 4.03

8.2 ± 5.02

16.4 ± 11.34

18.4 ± 11.86

30.8 ± 6.36

31.5 ± 8.56

97.0 ± 22.89

95.3 ± 25.02

17.9 ± 6.40

21.0 ± 12.40

49.0 ± 6.63

52.5 ± 6.05

90.0 ± 32.35

100.0 ± 65.26

164.0 ± 25.31

168.0 ± 29.98

82.0 ± 9.47

89.0 ± 12.75

X ± SD

1.9

3.6

8.2

6.9

12.0

14.0

31.9

31.1

93.0

96.5

16.0

17.0

51.5

54.0

79.5

79.5

163.0

169.0

81.0

90.5

Median

0.8-3.4

0.9-7.8

3.8-17.9

2.7-21.8

5.1-36.1

6.8-46.6

14.3-40

14.4-51.3

67-135

53-146

8-29

12-60

37-59

43-64

40-146

40-299

130-207

112-218

69-103

64-110

Min-Max

Control

Table 2. The plasma biochemical measurements of participants, pre- and poststudy.

–0.535

–0.47

–1.19

–0.53

–0.24

–0.17

–1.85

–0.66

–0.72

–1.85

Z

0.59

0.63

0.23

0.59

0.80

0.86

0.06

0.50

0.47

0.06

P

0.22
0.04*

0.52
0.66

0.10
0.04*

0.81
0.55

0.22
0.26

0.01*
0.02*

0.003*
0.11

0.01*
0.01*

0.24
0.38

0.28
0.06

P’
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Table 3. The plasma fatty acids levels of participants, pre- and poststudy.
Narcoleptic

Control

X ± SD (Before)

X ± SD (After)

X ± SD (Before)

X ± SD (After)

C14:0

16.83 ± 14.90

17.12 ± 9.53

12.69 ± 6.03

12.40 ± 5.23

C15:0

4.68 ± 2.02

5.08 ± 2.96

4.47 ± 2.07

4.04 ± 0.90

C16:0

408.77 ± 267.08

403.74 ± 212.83

397.70 ± 174.69

362.38 ± 51.02

C17:0

3.67 ± 1.83

3.81 ± 2.09

3.02 ± 1.31

3.37 ± 0.67

C18:0

178.52 ± 128.79

181.83 ± 115.51

144.62 ± 56.35

153.17 ± 28.99

C20:0

0.85 ± 0.35

0.58 ± 0.29

0.65 ± 0.28

0.60 ± 0.23

C22:0

1.36 ± 0.60

0.78 ± 0.41

0.64 ± 0.39

0.72 ± 0.34

C24:0

0.70 ± 0.45

0.46 ± 0.35

0.38 ± 0.11

0.30 ± 0.01

C16.1

12.62 ± 6.95 b

15.01 ± 7.25

18.59 ± 7.12

18.29 ± 3.91

C17:1

a, b

6.72 ± 2.88

5.49 ± 1.38

5.23 ± 0.53

5.05 ± 1.15

C18:1

505.11 ± 261.51

487.41 ± 248.47

C20:1

4.05 ± 1.06 a

5.54 ± 2.32

C22:1

5.92 ± 1.65 a

8.50 ± 3.78 b

C24:1

2.82 ± 0.81

a

C18:2 (n-6)

36.96 ± 85.48

C20:4 (n-6)

516.9 ± 237.14

443.82 ± 58.40

4.95 ± 1.93

4.25 ± 0.73

6.72 ± 1.80

0.42 ± 0.76

3.56 ± 1.05

3.49 ± 0.74

111.48 ± 52.09

116.30 ± 44.81

103.79 ± 12.22

13.45 ± 11.46 b

17.38 ± 17.29

23.45 ± 14.05

17.69 ± 5.24

C18:3 (n-3)

1.18 ± 0.83

1.26 ± 0.73

1.4 ± 0.31

1.35 ± 0.40

C20:5 (n-3)

8.57 ± 6.28

11.70 ± 6.29

12.11 ± 8.43

10.44 ± 3.78

C22:6 (n-3)

11.38 ± 7.59 a, b

55.79 ± 42.00 b

50.54 ± 45.82

63.67 ± 25.92

4.51 ± 1.98

b

a: P < 0.05 for intragroup values; b: P < 0.05 for intergroup values

Table 4. The correlation of plasma orexin levels with some plasma fatty acids of participants, pre- and poststudy.
Narcoleptic
Before

Control

After

Before

After

r

P

r

P

r

p

r

P

N-3 fatty acids (total)

0.800

0.10

–0.126

0.69

–1.000

0.03*

–0.209

0.53

C16:1

0.120

0.64

–0.674

0.006*

–0.121

0.68

–0.323

0.26

C20:5

0.115

0.65

–0.093

0.74

–0.55

0.04 *

–0.262

0.36

C20:1

–0.012

0.96

–0.530

0.04*

–0.257

0.37

–0.080

0.78

C22:6

0.424

0.10

–0.379

0.16

–0.547

0.04*

0.055

0.85

C22:0

0.407

0.16

–0.829

0.02*

–0.685

0.09

–0.200

0.80

*P < 0.05, Spearman
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this, there was no statistically significant difference in
the BMI values or body weights in the patient group
at the end of the study (P > 0.05) (Table 1).
It is known that the risk of abdominal obesity is
high in patients with narcolepsy (3). In the studies
performed, as only BMI findings were evaluated
and data such as waist and hip circumstances or
waist-to-hip ratio were not assessed, there were
various differences in interpretations (26). The
waist circumference (WC) measurement can give
some information about regional fat distribution.
The ideal WC measurements are 94 cm or 102 cm
in males, but values above 102 cm demonstrate
increased cardiovascular risk and fat accumulation
in the abdominal area (27). In this study, there was
no significance found in the WC measurements. A
change in this value was not seen at the end of study
(P > 0.05, Table 1). Contrary to these results, Kok et
al. (26) determined that the WC values were 101 cm
in males and 91 cm in females among 138 patients
with narcolepsy. It was also found that patients with
those WC values at high risk and at normal risk were
39% and 36%, respectively.
At the same time, the waist-to-hip ratio is the
simplest indicator of fat distribution, and this ratio
provides information about the amount of abdominal
fat. There is a relationship between this ratio and
chronic diseases (27). In this study, it was seen that
waist-to-hip ratio was within the normal limits in
both groups, both before and after the study (Table
1). In a study by Chabas et al. (24), it was detected
that there was no difference in the waist-to-hip ratio
of the patient and control groups (P > 0.05). Similarly,
it is seen in Table 1 that there was no difference in the
waist-to-hip ratio between the groups in this study
(P > 0.05).
After the studies mentioned above showing that
the plasma and CSF orexin levels in narcoleptics
are lower than those in healthy individuals, the level
of orexin was accepted as a diagnostic criterion for
the disease. The mean plasma orexin A levels of the
participants pre- and poststudy were found to be 31.5
pg/mL and 30.4 pg/mL in the patients and 31.5 pg/
mL and 30.8 pg/mL in the control group, respectively.
It was determined that the pre- and poststudy median
values of plasma orexin A levels of the patient group
were lower than the values for the control group, but
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the difference was not significant (P > 0.05, Table 2).
In a study similar to this study, by Dalal et al. (28),
it was determined that plasma orexin A levels in
11 narcoleptic and 20 healthy individuals without
narcolepsy were similar within the groups (P > 0.05).
A study by Nishino and Mignot (29) identified that the
plasma orexin A level was 11-25 pg/mL in 12 patients
with narcolepsy and 20-33 pg/mL in 12 healthy
individuals; they did not find a statistical significance
at this level between the 2 groups (P < 0.05).
In healthy individuals whose ages and BMI values
were similar to the subjects of this study, Igarashi et
al. (30) observed that plasma orexin A levels were
close to those found in our study.
As seen above, while the analysis results in some
of the studies are similar to those of this study, some
of them are different. This may because plasma
orexin A levels are influenced by the genetic factors
of the individuals, their sex, their age, and body
composition. At the same time, the number of
studied individuals and the period of the disease can
also cause different plasma orexin A levels.
In this study, plasma glucose, cholesterol,
triglyceride, HDL-C, VLDL-C, LDL-C, and insulin
levels, as well as plasma orexin A, were analyzed.
In various studies, it was reported that the lipid
profile of the individuals changed with n-3 fatty acid
supplementation. Williams et al. (25) administered
n-3 fatty acid supplementation of 2.7 g daily to 14
healthy individuals for 6 weeks without applying
a special diet. As a result of the study, plasma
triglyceride concentration decreased (P < 0.05) and
changes in the levels of LDL-C, VLDL-C, and HDL-C
were not observed (P > 0.05).
In another similar study, an n-3 supplement was
administered twice a day to 14 patients for 2 months
(378 mg eicosapentaenoic acid/capsule [EPA], 249 mg
docosahexaenoic acid/capsule [DHA]), and results
were compared with those of 13 healthy individuals
receiving a placebo (31). Similar to this study (Table
2), it was observed that there was no change in plasma
lipid profiles (cholesterol, triglyceride, HDL-C,
VLDL-C, LDL-C) within the group at the onset
of the study compared to the end of the study (P >
0.05). While the statistical significance in the levels
of plasma triglyceride, HDL-C, and VLDL-C at the
onset of the study was identified among the groups,

M. GEZMEN KARADAĞ, M. AKSOY

the difference in the levels of only plasma triglyceride
and VLDL-C at the end of the study was considered
significant (P < 0.05).
When Williams et al. (25) administered an n-3
fatty acid supplementation of 2.7 g daily to 14 healthy
individuals, they detected that there was no change in
the levels of plasma glucose and insulin after 6 weeks
(P > 0.05). In another similar study, it was observed
that there was no difference in plasma glucose
levels between 7 individuals receiving 1.5 g of DHA
supplementation daily for 9 weeks and the control
group at the end of study (32). In this study, a change
in the levels of plasma glucose was not observed
between the groups from the onset to the end of the
study (P > 0.05). In the patient group, the increase
is considered to result from the enhancing effect of
the systemic insulin level of n-3 supplementation
received during the study.
It was determined that the levels of monoaminergic
neurotransmitters, which are dopamine, serotonin,
and norepinephrine, decreased in the frontal cortex
region of the brains of laboratory animals fed on
insufficient essential fatty acids. When arachidonic
acid (AA) and DHA were added to the diet, the
decrease in these monoaminergic neurotransmitters
was prevented (16). In this study, although plasma
orexin A levels of the patients did not change after
the administration of n-3 supplementation (P > 0.05),
it was seen that there was a decrease in serotonin
levels in the patients with narcolepsy at the end of
the study, in contrast to other studies, and there was
a difference in plasma serotonin levels between the
patient and control groups as a result of the study (P
< 0.05, Table 2). In this study, the level of serotonin in
the brain was not researched; it is considered that the
serotonin level in plasma decreases with the increase
of serotonin in some parts of the brain. A large
amount of polyunsaturated fatty acid intake increases
the viscosity of the membrane, and this also affects
the protein structures in the membrane and their
functions. It has been announced that a large amount
of polyunsaturated fatty acid intake, especially in the
brain, causes the reduction of the proteins carrying
serotonin (33). However, if it is remembered that the
n-3 fatty acids administered in the study were not in
high doses, it is unknown how these fatty acids show
the reduction effect on the serotonin carrier proteins

and decrease the serotonin concentration.
Maximum therapeutic effects of EPA and DHA
received in high pharmacological doses have been
examined in many clinical trials. Due to the mistakes
in food consumption records for the determining
amounts of dietary EPA and DHA intake, some
problems arose in these studies. It was stated that
high doses of EPA and DHA are inappropriate for
administration into the blood directly because they
could cause some metabolic abnormalities; dietary
supplementation was reported to be more reliable
(34). However, fish oil supplementation including
a pharmacological dose of n-3 is suggested to be
used in the long term. It generally includes 1 capsule
of 300 or 500 mg of n-3 fatty acid, and it is stated
that approximately 4-6 g of n-3 fatty acid intake
(15-20 capsules/day) will cause clinical adverse
effects. The study results showed that the usage
of fish oil supplementation, including EPA and
DHA, did not cause major adverse effects, but there
were gastrointestinal system symptoms in some
individuals because of the number of capsules and
their sizes (35). During this trial, an adverse effect of
supplementation of fish oil including n-3 fatty acids
(760 mg of EPA, 320 mg of DHA) was not observed.
Similar to the size of the dose in the study, an adverse
effect of the supplement was not observed in other
various clinical trials in which n-3 was administered.
Peet and Horrobin (36) observed an adverse effect
frequency of 16% in the patients to whom they
administered 1, 2, and 4 g of EPA.
After the dietary intake of EPA and DHA, their
levels are enhanced in plasma and the brain. When
EPA is received in lower doses than DHA, its level
in plasma increases, whereas the level of DHA in
the plasma increases with approximately 2 g of daily
intake (34). In a metaanalysis of 12 different studies
in which plasma DHA level was examined after DHA
supplementation, it was determined that plasma
DHA level increased depending on the dose after
the administration of 0.2-6 g of DHA during 1-6
months (34). However, in some of the clinical studies
examined, it was indicated that the plasma DHA level
does not completely reflect the brain or synaptic DHA
density. After DHA supplementation, it was observed
that plasma DHA levels and plasma EPA levels
increased. A fatty acid increase of about 0.4 g/100
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g in EPA concentration is observed after a daily 1-g
dietary DHA intake. In the same metaanalysis study,
an increase in plasma EPA and DHA concentrations
after daily 4-g EPA supplementation was detected.
In the studies performed, it was determined that
plasma EPA and DHA levels increased after EPA and
DHA intake, as well as after fish oil supplementation
including these fatty acids (34).
In a study by Hamazaki (37), 41 students took
either DHA-rich oil capsules containing 1.5-1.8 g of
DHA each day (17 females, 5 males) or control oil
capsules containing 97% soybean oil plus 3% fish
oil (12 females, 7 males) for 3 months. At the end
of the study, compared with the onset of the study,
there were statistically significant differences in the
plasma EPA level of the control group and in the
plasma C16:0, C18:1, EPA, and DHA levels of the
other group (P < 0.05). Similarly, as seen in Table 3,
at the end of this study compared with the onset of
the study, DHA levels in the plasma of the patient
group increased and significant differences in plasma
C17:1, C20:1, C22:1, and C24:1 levels were detected
(P < 0.05). In the control group, a significant change
was not observed for plasma fatty acids at the end of
the study compared with the onset of the study (P >
0.05). Statistically significant differences in the levels
of C22:1, C24:1, and C22:6 at the end of the study
and of C16:1, C17:1, C20:4, and C22:6 in the plasma
at the onset of the study between the groups were
determined in this study (P < 0.05).
It has been stated that orexin neurons such as some
other hypothalamic neuropeptides are positively
related to lipid circulation. In the paraventricular
nucleus and perifornical hypothalamus, orexin
production is stimulated by the dietary fat intake and
fat circulation (13,17). Dziedzic et al. (38) identified
that prepro-orexin mRNA expression in the lateral
hypothalamus increased in rats fed with large
amounts of n-3 compared to those fed small amounts
of n-3 fatty acids.
In a study by Chang et al. (13), it was detected
that orexin expression increased by 20% due to the
injection of a 20% fat solution in rats with normal
weight. In a similar study, investigators detected that
orexin mRNA expression in the lateral hypothalamus
increased in rats fed a high-fat diet (73.7% of the
energy) (12).
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In this study, a correlation between plasma orexin
A levels and plasma n-3 fatty acids was observed at
the onset of the study in the control group (r = –1.00).
It was interesting to note that there was a very low
correlation level at the end (r = –0.209). Similarly,
with C22:6, at the beginning there was a negative and
significant correlation (r = –0.547), whereas at the
end, it was positive and insignificant (r = 0.055). In
the narcoleptic group, orexin showed a positive, high
correlation with n-3 fatty acids (r = 0.80), whereas
at the end, it was negative and very low (r = –0.126)
(Table 4). These results could be related to the amount
of dietary fatty acid intake in the patient and control
groups. The dietary n-3 fatty acid intake can alter the
results and the correlations.
It can be seen in Table 4 that a correlation between
plasma orexin A levels and some fatty acids was
observed after n-3 supplementation. We possess
complete information related to the effects of fat and
fatty acids on hypothalamic peptide systems such as
orexin (13). At the same time, as orexin has only been
recently discovered and is known as a hypothalamic
peptide, it is difficult to compare our study findings
with other study results. In other studies performed,
the plasma orexin A level was not taken into account.
This made it difficult to interpret the strength of our
study and to compare the results with those of other
studies.
Conclusion
It was observed that a daily dose of 1.4 g of n-3
fatty acid supplement did not increase plasma levels
of orexin A over the course of 2 months, but it did
affect some other biochemical parameters. The
results of the current study should be considered as
preliminary findings. Future studies with a larger
sample size, longer duration of study, and more doses
of supplements are necessary for obtaining clear
results.
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